Executive Chairman and CEO Miguel Martin dismissed the hostile bid as a transparent effort to pressure shareholders into a short-term decision that ignores Aurora’s long-term growth. According to the company, Curaleaf’s public assertions regarding Aurora’s operations—specifically regarding cultivation output and the impact of German regulatory changes—are inaccurate and outdated. Aurora contends that its international strategy is delivering results, pointing to a 17% year-over-year increase in international net revenue and three consecutive years of positive adjusted EBITDA.

Management emphasized that the company is at a pivotal inflection point, bolstered by recent acquisitions in the UK and a leading market share in Poland. Aurora maintains that its EU-GMP-certified facilities possess specialized scientific and regulatory capabilities that remain undervalued by the current offer. Until the newly formed special committee completes its assessment and provides a formal recommendation, the board has advised shareholders to take no action regarding the Curaleaf proposal.